HRTX
Heron Therapeutics, Inc. /De/
$0.43
0.00 (-0.90%)
At close · Jul 7
Market Cap
$84.32M
Shares
189,279,369
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$154.9M
+7.4%
FY2025
Net Income
-$20.2M
-48.7%
FY2025
Gross Margin
73.31%
+0.1pp
FY2025
Operating Margin
-1.64%
+6.4pp
FY2025
Diluted EPS
-$0.12
-33.3%
FY2025
Operating Cash Flow
-$27.59M
-22.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $173M – $183M | $150.71M | $154.9M | $144.29M | $127.04M | $107.67M | $86.35M | $88.64M | $145.97M | $77.47M | $30.77M | $1.28M | — | — | — | — | — | — | — | |
| — | $43.53M | $41.35M | $38.65M | $65.11M | $54.87M | $46.02M | $36.19M | $61.62M | $27.51M | $4.59M | $35K | — | — | — | — | — | — | — | |
| — | $107.18M | $113.56M | $105.64M | $61.94M | $52.8M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | 73.31% | 73.21% | 48.75% | 49.04% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $12.54M | $12.43M | $16.68M | $39.13M | $82.7M | $130.82M | $174.53M | $167.38M | $140.03M | $138.58M | $103.13M | $61.18M | $54.83M | $32.52M | $15.17M | $8.21M | $7.26M | $7.8M | |
| — | $51.06M | $49.06M | $47.09M | $67.64M | $82.51M | $87.18M | $63.85M | $89.76M | $64.6M | $56.6M | $47.67M | $17.35M | $8.71M | — | — | — | — | — | |
| — | $54.05M | $54.61M | $53.4M | $65.78M | $62.24M | $40.15M | $42.23M | $37.9M | $29.26M | $25.55M | $21.37M | $18.4M | $11.02M | $21.94M | $8.66M | $3.5M | $3.97M | $3.71M | |
| — | — | $2.31M | $2.49M | $2.9M | $2.89M | $3.02M | $2.85M | $2.04M | $1.51M | $1.53M | $1.1M | $734K | $578K | $333K | $197K | $179K | $227K | $356K | |
| — | — | — | $5.4M | $5.4M | $5.4M | $1.6M | $5.6M | — | — | — | — | — | — | — | — | — | — | — | |
| — | $294.16M | — | — | — | — | — | — | — | $261.41M | $225.33M | $172.19M | $96.93M | $74.56M | $54.46M | $23.83M | $11.71M | $11.24M | $11.5M | |
| — | $117.64M | $116.1M | $117.17M | $172.55M | $227.46M | $304.17M | $316.8M | $356.66M | $261.41M | $225.33M | — | — | — | — | — | — | — | — | |
| — | -$10.46M | -$2.54M | -$11.53M | -$110.62M | -$174.66M | -$217.83M | -$228.16M | -$210.69M | -$183.94M | -$194.56M | -$170.92M | -$96.93M | -$74.56M | -$54.46M | -$23.83M | -$11.06M | -$9.93M | -$10.24M | |
| — | — | -1.64% | -7.99% | -87.07% | -162.21% | -252.27% | -257.41% | -144.34% | -237.42% | -632.36% | -13363.17% | — | — | — | — | — | — | — | |
| — | — | -$224K | -$9.04M | -$107.72M | -$171.77M | -$214.81M | -$225.32M | -$208.65M | -$182.42M | -$193.03M | -$169.82M | -$96.19M | -$73.98M | -$54.12M | -$23.63M | -$10.88M | -$9.71M | -$9.89M | |
| — | — | $9.61M | $6.03M | $3.87M | $2.47M | $2.41M | $1.9M | $1.47M | $2.67M | $3.94M | $2.66M | $958K | $887K | $828K | $605K | — | — | — | |
| — | — | $1.95M | $3.55M | $3.36M | $1.64M | $433K | $3.63M | $7.26M | $5.97M | $1.05M | $445K | $174K | — | — | — | — | — | — | |
| — | -$20.48M | -$17.66M | -$2.05M | $56K | -$7.37M | -$2.86M | $885K | $5.95M | $5.1M | -$2.93M | -$2.23M | -$666K | -$1.81M | -$826K | -$599K | — | $240K | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$11.44M | -$7.2M | -$10.22M | |
| — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | -$122K | |
| — | -$30.94M | -$20.2M | -$13.58M | -$110.56M | -$182.02M | -$220.68M | -$227.28M | -$204.75M | -$178.84M | -$197.48M | -$173.14M | -$97.59M | -$76.37M | -$55.28M | -$23.35M | -$11.81M | -$7.35M | -$10.03M | |
| — | — | -13.04% | -9.41% | -87.02% | -169.05% | -255.58% | -256.41% | -140.27% | -230.84% | -641.87% | -13537.37% | — | — | — | — | — | — | — | |
| — | -$30.95M | -$20.2M | -$13.58M | -$110.53M | -$182.04M | -$220.95M | -$227.11M | -$204.58M | -$178.92M | -$197.48M | -$173.12M | -$97.63M | -$76.37M | -$55.28M | -$23.35M | -$11.81M | -$7.35M | — | |
| USD/shares | — | — | -$0.12 | -$0.09 | -$0.80 | -$1.67 | -$2.24 | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | -$0.12 | -$0.09 | -$0.80 | -$1.67 | -$2.24 | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 166.71M | 152.45M | 138.14M | 108.88M | 98.47K | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | — | — |
| shares | — | — | 166.71M | 152.45M | 138.14M | 108.88M | 98.47K | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| CINVANTI | $96,758,000 | $100,079,000 | $94,869,000 | $87,245,000 | $73,507,000 | $87,815,000 | $132,162,000 | $56,200,000 |
| ZYNRELEF | $38,072,000 | $25,546,000 | $17,727,000 | $10,196,000 | $2,924,000 | — | — | — |
| Aponvie | $11,571,000 | $4,518,000 | $1,391,000 | — | — | — | — | — |
| SUSTOL | $8,503,000 | $14,142,000 | $13,057,000 | $10,231,000 | $9,915,000 | $823,000 | $13,806,000 | $21,300,000 |